KYKO.Y Stock Overview
Engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Kyowa Kirin Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥14.66 |
| 52 Week High | JP¥19.85 |
| 52 Week Low | JP¥14.66 |
| Beta | 0.22 |
| 1 Month Change | -9.42% |
| 3 Month Change | -9.59% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| KYKO.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.8% | 0.5% | 0.7% |
| 1Y | n/a | 2.2% | 23.0% |
Return vs Industry: Insufficient data to determine how KYKO.Y performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KYKO.Y performed against the US Market.
Price Volatility
| KYKO.Y volatility | |
|---|---|
| KYKO.Y Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KYKO.Y's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KYKO.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,974 | Masashi Miyamoto | www.kyowakirin.com |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.
Kyowa Kirin Co., Ltd. Fundamentals Summary
| KYKO.Y fundamental statistics | |
|---|---|
| Market cap | US$7.44b |
| Earnings (TTM) | US$527.49m |
| Revenue (TTM) | US$3.15b |
14.1x
P/E Ratio2.4x
P/S RatioIs KYKO.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYKO.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥498.98b |
| Cost of Revenue | JP¥128.24b |
| Gross Profit | JP¥370.74b |
| Other Expenses | JP¥287.20b |
| Earnings | JP¥83.54b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 164.12 |
| Gross Margin | 74.30% |
| Net Profit Margin | 16.74% |
| Debt/Equity Ratio | 0% |
How did KYKO.Y perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield37%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 10:43 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kyowa Kirin Co., Ltd. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiro Yoshinaga | Aizawa Securities Co. Ltd. |
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |